Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma

NCT01309789 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT01309789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01309789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2011
Completion date
February 28, 2017
Enrollment
39 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, large-cell, anaplastic, lymphoma, nk-cell, lymphoma, t-cell